Despite the advances of medicine, it is still the case that an estimated 2.2 million cancers worldwide are caused by infectious agents, with Human Papillomavirus (HPV) ranking as the second-leading cause among pathogen-driven cancers.1
The CDC’s numbers paint a bleak picture of this preventable infection, showing HPV as responsible for2:
Despite widespread vaccination efforts, cancer-causing subtypes of HPV continue to affect more than 42 million Americans,3 highlighting the critical importance of early detection. The need has never been greater for laboratories to have access to rapid and accurate molecular testing for high-risk HPV subtypes.
Our new Human Papillomavirus (HPV) Simplicity Panel™ was designed to address the challenges seen in other PCR platforms. Not only does it detect the 14 high-risk HPV types associated with cervical, anal, penile, and oropharyngeal cancers (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), but it does so using the same pre-plated, breakaway format our customers have come to rely on to streamline their workflows.
SimplicityTM is renowned for improving PCR testing in several important ways:
These upgrades translate directly into impact—labs using our SimplicityTM format can see an 82% decrease in hands-on time. And every meaningful workflow improvement expands your lab’s ability to respond quickly and effectively when it matters most.
HPV remains one of the most prevalent viral infections in the U.S., yet many research laboratories lack the tools to track, study, and differentiate its high-risk genotypes efficiently.
The Human Papillomavirus (HPV) Simplicity Panel™ can help laboratories of all sizes generate meaningful, reliable data that supports the ongoing fight against HPV-related diseases through research.